Identification

Name
Clarithromycin
Accession Number
DB01211  (APRD00181)
Type
Small Molecule
Groups
Approved
Description

Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.

Structure
Thumb
Synonyms
  • 6-O-methyl erythromycin
  • 6-O-Methylerythromycin
  • 6-O-Methylerythromycin a
  • CLA
  • CLARITHROMYCIN
  • Clarithromycina
  • Clarithromycine
  • Clarithromycinum
External IDs
A-56268 / ABBOTT-56268 / TE-031
Product Ingredients
IngredientUNIICASInChI Key
Clarithromycin citrate16K08R7NG0848130-51-8MDRWXDRMSKEMRE-AZFLODHXSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Clarithromycin XLTablet, extended release500 mgOralActavis Pharma Company2014-12-01Not applicableCanada
BiaxinTablet, film coated, extended release500 mg/1OralAbbvie2000-03-032016-10-13Us
BiaxinTablet, film coated250 mg/1OralAbbvie1991-10-312017-04-26Us
BiaxinGranule, for suspension125 mgOralBgp Pharma Ulc1995-12-31Not applicableCanada
BiaxinGranule, for suspension250 mg/5mLOralPhysicians Total Care, Inc.2007-05-01Not applicableUs
BiaxinTablet, film coated250 mg/1OralRemedy Repack2013-03-132017-04-14Us
BiaxinTablet, film coated500 mg/1OralAbbvie1991-10-312017-07-30Us
BiaxinTablet, film coated500 mg/1OralCardinal Health1991-10-312018-03-12Us
BiaxinGranule, for suspension250 mgOralBgp Pharma Ulc2002-05-28Not applicableCanada
BiaxinTablet, film coated, extended release500 mg/1OralA S Medication Solutions2000-03-032017-06-20Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-clarithromycinTablet250 mgOralApotex Corporation2007-07-26Not applicableCanada
Apo-clarithromycinTablet500 mgOralApotex Corporation2007-07-26Not applicableCanada
Apo-clarithromycin XLTablet, extended release500 mgOralApotex Corporation2014-09-03Not applicableCanada
Ava-clarithromycinTablet250 mgOralAvanstra Inc2011-09-192014-08-21Canada
Ava-clarithromycinTablet500 mgOralAvanstra Inc2011-09-192014-08-21Canada
ClarithromycinFor suspension250 mg/5mLOralSandoz2007-09-04Not applicableUs
ClarithromycinGranule, for suspension125 mg/5mLOralRanbaxy Inc.2007-10-03Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralLannett Company, Inc.2015-12-04Not applicableUs
ClarithromycinTablet, film coated500 mg/1OralA S Medication Solutions2006-05-312017-06-20Us
ClarithromycinTablet, coated250 mg/1OralA S Medication Solutions2004-05-252017-06-20Us
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Apo-lansoprazole-amoxicillin-clarithromycinClarithromycin (500 mg) + Amoxicillin (500 mg) + Lansoprazole (30 mg)Capsule; Capsule, delayed release; Kit; TabletOralApotex CorporationNot applicableNot applicableCanada
Hp-pacClarithromycin (500 mg) + Amoxicillin (500 mg) + Lansoprazole (30 mg)Capsule; Capsule, delayed release; Kit; TabletOralTakeda1998-08-18Not applicableCanada
Lansoprazole, Amoxicillin and ClarithromycinClarithromycin (500 mg/1) + Amoxicillin (500 mg/1) + Lansoprazole (30 mg/1)KitSandoz2014-03-04Not applicableUs
Lansoprazole, Amoxicillin and ClarithromycinClarithromycin (500 mg/1) + Amoxicillin (500 mg/1) + Lansoprazole (30 mg/1)KitPrasco, Laboratories2015-03-03Not applicableUs
Lansoprazole, Amoxicillin, and ClarithromycinClarithromycin + Amoxicillin + LansoprazoleKitTeva2013-09-092016-10-21Us00093 8055 14 nlmimage10 c2386123
Lansoprazole, Amoxicillin, ClarithromycinClarithromycin + Amoxicillin + LansoprazoleKitRising Health, Llc.2016-10-14Not applicableUs
Omeclamox-PakClarithromycin + Amoxicillin + OmeprazoleKitCumberland Pharmaceuticals2012-04-27Not applicableUs
Omeclamox-PakClarithromycin + Amoxicillin + OmeprazoleKitPernix Therapeutics2012-04-272017-12-22Us
PrevpacClarithromycin (500 mg/1) + Amoxicillin (500 mg/1) + Lansoprazole (30 mg/1)KitPhysicians Total Care, Inc.2005-05-20Not applicableUs
PrevpacClarithromycin (500 mg/1) + Amoxicillin (500 mg/1) + Lansoprazole (30 mg/1)KitTakeda1997-12-02Not applicableUs
International/Other Brands
Klacid XL / Klaricid XL / Macladin / Naxy / Veclam / Zeclar
Categories
UNII
H1250JIK0A
CAS number
81103-11-9
Weight
Average: 747.9534
Monoisotopic: 747.476891299
Chemical Formula
C38H69NO13
InChI Key
AGOYDEPGAOXOCK-KCBOHYOISA-N
InChI
InChI=1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1
IUPAC Name
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-12,13-dihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione
SMILES

Pharmacology

Indication

An alternative medication for the treatment of acute otitis media caused by H. influenzae, M. catarrhalis, or S. pneumoniae in patients with a history of type I penicillin hypersensitivity. Also for the treatment of pharyngitis and tonsillitis caused by susceptible Streptococcus pyogenes, as well as respiratory tract infections including acute maxillary sinusitis, acute bacterial exacerbations of chronic bronchitis, mild to moderate community-acquired pneuomia, Legionnaires' disease, and pertussis. Other indications include treatment of uncomplicated skin or skin structure infections, helicobacter pylori infection, duodenal ulcer disease, bartonella infections, early Lyme disease, and encephalitis caused by Toxoplasma gondii (in HIV infected patients in conjunction with pyrimethamine). Clarithromycin may also decrease the incidence of cryptosporidiosis, prevent the occurence of α-hemolytic (viridans group) streptococcal endocarditis, as well as serve as a primary prevention for Mycobacterium avium complex (MAC) bacteremia or disseminated infections (in adults, adolescents, and children with advanced HIV infection).

Structured Indications
Pharmacodynamics

Clarithromycin is a macrolide antibiotic whose spectrum of activity includes many gram-positive (Staphylococcus aureus, S. pneumoniae, and S. pyogenes) and gram-negative aerobic bacteria (Haemophilus influenzae, H. parainfluenzae, and Moraxella catarrhalis), many anaerobic bacteria, some mycobacteria, and some other organisms including Mycoplasma, Ureaplasma, Chlamydia, Toxoplasma, and Borrelia. Other aerobic bacteria that clarithromycin has activity against include C. pneumoniae and M. pneumoniae. Clarithromycin has an in-vitro activity that is similar or greater than that of erythromycin against erythromycin-susceptible organisms. Clarithromycin is usually bacteriostatic, but may be bactericidal depending on the organism and the drug concentration.

Mechanism of action

Clarithromycin is first metabolized to 14-OH clarithromycin, which is active and works synergistically with its parent compound. Like other macrolides, it then penetrates bacteria cell wall and reversibly binds to domain V of the 23S ribosomal RNA of the 50S subunit of the bacterial ribosome, blocking translocation of aminoacyl transfer-RNA and polypeptide synthesis. Clarithromycin also inhibits the hepatic microsomal CYP3A4 isoenzyme and P-glycoprotein, an energy-dependent drug efflux pump.

TargetActionsOrganism
A50S ribosomal protein L10
inhibitor
Shigella flexneri
UPotassium voltage-gated channel subfamily H member 2Not AvailableHuman
USolute carrier organic anion transporter family member 1B1Not AvailableHuman
USolute carrier organic anion transporter family member 1B3Not AvailableHuman
Absorption

Clarithromycin is well-absorbed, acid stable and may be taken with food.

Volume of distribution
Not Available
Protein binding

~ 70% protein bound

Metabolism

Hepatic - predominantly metabolized by CYP3A4 resulting in numerous drug interactions.

Route of elimination

After a 250 mg tablet every 12 hours, approximately 20% of the dose is excreted in the urine as clarithromycin, while after a 500 mg tablet every 12 hours, the urinary excretion of clarithromycin is somewhat greater, approximately 30%.

Half life

3-4 hours

Clearance
Not Available
Toxicity

Symptoms of toxicity include diarrhea, nausea, abnormal taste, dyspepsia, and abdominal discomfort. Transient hearing loss with high doses has been observed. Pseudomembraneous colitis has been reported with clarithromycin use. Allergic reactions ranging from urticaria and mild skin eruptions to rare cases of anaphylaxis and Stevens-Johnson syndrome have also occurred. Rare cases of severe hepatic dysfunctions also have been reported. Hepatic failure is usually reversible, but fatalities have been reported. Clarithromycin may also cause tooth decolouration which may be removed by dental cleaning. Fetal abnormalities, such as cardiovascular defects, cleft palate and fetal growth retardation, have been observed in animals. Clarithromycin may cause QT prolongation.

Affected organisms
  • Enteric bacteria and other eubacteria
  • Mycobacterium
  • Streptococcus pyogenes
  • Streptococcus pneumoniae
  • Haemophilus influenzae
  • Helicobacter pylori
  • Mycobacterium leprae
  • Mycobacterium avium
Pathways
PathwayCategory
Clarithromycin Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with 1,10-Phenanthroline.Experimental
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Clarithromycin.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Clarithromycin.Experimental, Illicit
3,4-DichloroisocoumarinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with 3,4-Dichloroisocoumarin.Experimental
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Clarithromycin.Experimental, Illicit
AbemaciclibThe risk or severity of adverse effects can be increased when Clarithromycin is combined with Abemaciclib.Approved, Investigational
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Clarithromycin.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Clarithromycin.Approved, Investigational
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Clarithromycin.Approved
Acetyl sulfisoxazoleThe metabolism of Clarithromycin can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Clarithromycin.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be increased when it is combined with Clarithromycin.Experimental
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Clarithromycin.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Clarithromycin.Approved
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Clarithromycin.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Clarithromycin.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Clarithromycin.Experimental, Investigational
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Clarithromycin.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Clarithromycin.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Clarithromycin.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Clarithromycin.Approved
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Clarithromycin.Approved, Investigational
AlogliptinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Alogliptin.Approved
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Clarithromycin.Approved, Withdrawn
Alpha-1-proteinase inhibitorThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Alpha-1-proteinase inhibitor.Approved
alpha-Tocopherol acetateThe metabolism of alpha-Tocopherol acetate can be decreased when combined with Clarithromycin.Approved
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Clarithromycin.Approved, Illicit, Investigational
AmantadineAmantadine may increase the QTc-prolonging activities of Clarithromycin.Approved
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Clarithromycin.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Clarithromycin.Approved, Investigational
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Clarithromycin.Experimental, Investigational
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Clarithromycin.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Clarithromycin.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Clarithromycin.Approved
AmiodaroneClarithromycin may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Clarithromycin.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Clarithromycin.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Clarithromycin.Approved
AmprenavirThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Amprenavir.Approved, Investigational
AnagrelideClarithromycin may increase the QTc-prolonging activities of Anagrelide.Approved
AndrostenedioneThe serum concentration of Androstenedione can be increased when it is combined with Clarithromycin.Experimental, Illicit
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Clarithromycin.Investigational
anecortave acetateThe serum concentration of anecortave acetate can be increased when it is combined with Clarithromycin.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Clarithromycin.Approved, Investigational
Antithrombin III humanThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Antithrombin III human.Approved
ApalutamideThe serum concentration of Apalutamide can be increased when it is combined with Clarithromycin.Approved, Investigational
ApixabanThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Apixaban.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
ApremilastThe metabolism of Apremilast can be decreased when combined with Clarithromycin.Approved, Investigational
AprepitantThe serum concentration of Clarithromycin can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Aprotinin.Approved, Investigational, Withdrawn
ArformoterolArformoterol may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
ArgatrobanThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Clarithromycin.Approved, Investigational
ArmodafinilThe metabolism of Clarithromycin can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideClarithromycin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherClarithromycin may increase the QTc-prolonging activities of Artemether.Approved
AsenapineClarithromycin may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Clarithromycin.Approved, Withdrawn
AsunaprevirThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Asunaprevir.Approved, Investigational, Withdrawn
AtamestaneThe serum concentration of Atamestane can be increased when it is combined with Clarithromycin.Investigational
AtazanavirThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Clarithromycin can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Clarithromycin.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Clarithromycin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Clarithromycin.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Clarithromycin.Approved
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Clarithromycin.Approved
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Clarithromycin.Investigational
BaricitinibThe metabolism of Baricitinib can be decreased when combined with Clarithromycin.Approved, Investigational
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Clarithromycin.Approved
BatimastatThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Batimastat.Experimental
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Clarithromycin.Investigational
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Clarithromycin.Approved, Investigational
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Clarithromycin.Approved
BenazeprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Benazepril.Approved, Investigational
BenidipineThe metabolism of Benidipine can be decreased when combined with Clarithromycin.Approved, Investigational
BenzamidineThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Benzamidine.Experimental
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Clarithromycin.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Clarithromycin.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Clarithromycin.Approved, Vet Approved
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Clarithromycin.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Clarithromycin.Approved, Investigational
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Clarithromycin.Approved
BictegravirThe metabolism of Bictegravir can be decreased when combined with Clarithromycin.Approved, Investigational
BioallethrinThe metabolism of Bioallethrin can be decreased when combined with Clarithromycin.Approved, Experimental
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Clarithromycin.Approved
BivalirudinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Bivalirudin.Approved, Investigational
BlonanserinThe metabolism of Blonanserin can be decreased when combined with Clarithromycin.Approved, Investigational
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Clarithromycin.Approved, Withdrawn
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Clarithromycin.Approved, Investigational
BosentanThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Clarithromycin.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Clarithromycin.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Clarithromycin.Approved, Investigational
BrigatinibThe serum concentration of Brigatinib can be increased when it is combined with Clarithromycin.Approved, Investigational
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Clarithromycin.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Clarithromycin.Approved, Investigational
BromazepamThe metabolism of Bromazepam can be decreased when combined with Clarithromycin.Approved, Illicit, Investigational
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Clarithromycin.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Clarithromycin.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Clarithromycin.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Clarithromycin.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Clarithromycin.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Clarithromycin.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
BuspironeThe metabolism of Buspirone can be decreased when combined with Clarithromycin.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Clarithromycin.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Clarithromycin.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Clarithromycin.Approved
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Clarithromycin.Approved, Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Clarithromycin.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Clarithromycin.Approved, Nutraceutical
CamostatThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Camostat.Experimental
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Clarithromycin.Approved
CandoxatrilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Candoxatril.Experimental
CandoxatrilatThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Candoxatrilat.Experimental
CannabidiolThe metabolism of Cannabidiol can be decreased when combined with Clarithromycin.Approved, Investigational
CaptoprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Captopril.Approved
CarbamazepineThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Clarithromycin.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Clarithromycin.Approved, Investigational
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Clarithromycin.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Clarithromycin.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Clarithromycin.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Clarithromycin.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Clarithromycin.Approved, Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Clarithromycin.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Clarithromycin.Approved
ChloramphenicolThe metabolism of Clarithromycin can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Clarithromycin.Approved, Illicit, Investigational
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Clarithromycin.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Clarithromycin.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Clarithromycin.Approved, Nutraceutical
CholesterolThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Cholesterol.Approved, Experimental, Investigational
ChymostatinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Chymostatin.Experimental
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Clarithromycin.Approved, Investigational
CilastatinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Cilastatin.Approved, Investigational
CilazaprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Clarithromycin.Approved, Investigational
CimetidineThe metabolism of Clarithromycin can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Clarithromycin.Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Clarithromycin.Approved, Investigational, Withdrawn
CitalopramClarithromycin may increase the QTc-prolonging activities of Citalopram.Approved
ClemastineThe metabolism of Clarithromycin can be decreased when combined with Clemastine.Approved, Investigational
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Clarithromycin.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Clarithromycin.Approved, Illicit
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Clarithromycin.Approved, Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Clarithromycin.Approved
ClobetasoneThe serum concentration of Clobetasone can be increased when it is combined with Clarithromycin.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Clarithromycin.Approved
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Clarithromycin.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Clarithromycin.Approved, Investigational
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Clarithromycin.Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Clarithromycin.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Clarithromycin.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Clarithromycin.Approved
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Clarithromycin.Approved, Illicit
ClorindioneThe serum concentration of Clorindione can be increased when it is combined with Clarithromycin.Experimental
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Clarithromycin.Approved, Illicit
ClotrimazoleThe metabolism of Clarithromycin can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Clarithromycin.Approved
CobicistatThe serum concentration of Cobicistat can be increased when it is combined with Clarithromycin.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Clarithromycin.Approved, Investigational
CocaineThe metabolism of Cocaine can be decreased when combined with Clarithromycin.Approved, Illicit
CodeineThe metabolism of Codeine can be decreased when combined with Clarithromycin.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Clarithromycin.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Clarithromycin.Approved, Investigational
Conjugated estrogensThe metabolism of Conjugated estrogens can be decreased when combined with Clarithromycin.Approved
CopanlisibThe metabolism of Copanlisib can be decreased when combined with Clarithromycin.Approved, Investigational
Cortexolone 17α-propionateThe serum concentration of Cortexolone 17α-propionate can be increased when it is combined with Clarithromycin.Investigational
CorticosteroneThe serum concentration of Corticosterone can be increased when it is combined with Clarithromycin.Experimental
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Clarithromycin.Approved, Investigational
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Clarithromycin.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Clarithromycin.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Clarithromycin.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
CymarinThe serum concentration of Cymarin can be increased when it is combined with Clarithromycin.Experimental
CytarabineThe metabolism of Cytarabine can be decreased when combined with Clarithromycin.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Clarithromycin.Approved
DabrafenibThe serum concentration of Clarithromycin can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Clarithromycin.Approved, Investigational
DantroleneThe metabolism of Dantrolene can be decreased when combined with Clarithromycin.Approved, Investigational
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Clarithromycin.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Clarithromycin.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Clarithromycin.Approved, Investigational
DarexabanThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Darexaban.Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Clarithromycin.Approved, Investigational
DarunavirThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Clarithromycin.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Clarithromycin.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Clarithromycin.Approved
DeferasiroxThe serum concentration of Clarithromycin can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe metabolism of Deflazacort can be decreased when combined with Clarithromycin.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Clarithromycin.Approved
DelamanidClarithromycin may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
DelanzomibThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Delanzomib.Investigational
DelaprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Delapril.Experimental
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Clarithromycin.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Clarithromycin.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
DeslanosideThe serum concentration of Deslanoside can be increased when it is combined with Clarithromycin.Approved
DesonideThe serum concentration of Desonide can be increased when it is combined with Clarithromycin.Approved, Investigational
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Clarithromycin.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Clarithromycin.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Clarithromycin.Experimental, Vet Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Clarithromycin.Approved, Investigational
DeutetrabenazineClarithromycin may increase the QTc-prolonging activities of Deutetrabenazine.Approved, Investigational
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Clarithromycin.Vet Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Clarithromycin.Approved
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Clarithromycin.Approved, Investigational
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Clarithromycin.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Clarithromycin.Approved, Illicit, Investigational, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Clarithromycin.Approved, Illicit, Investigational, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Clarithromycin.Approved, Vet Approved
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Clarithromycin.Approved
DienogestThe serum concentration of Dienogest can be increased when it is combined with Clarithromycin.Approved
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Clarithromycin.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Clarithromycin.Approved, Investigational, Withdrawn
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Clarithromycin.Approved
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Clarithromycin.Approved, Investigational
DigoxinThe metabolism of Digoxin can be decreased when combined with Clarithromycin.Approved
Digoxin Immune Fab (Ovine)The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Clarithromycin.Approved
Dihydro-alpha-ergocryptineThe metabolism of Dihydro-alpha-ergocryptine can be decreased when combined with Clarithromycin.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Clarithromycin.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Clarithromycin.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Clarithromycin.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Clarithromycin.Experimental
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Clarithromycin.Approved, Investigational
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Clarithromycin.Approved, Investigational
DiphenadioneThe serum concentration of Diphenadione can be increased when it is combined with Clarithromycin.Experimental
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
DisopyramideClarithromycin may increase the QTc-prolonging activities of Disopyramide.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Clarithromycin.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Clarithromycin.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Clarithromycin.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Clarithromycin.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Clarithromycin.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Clarithromycin.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Clarithromycin.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Clarithromycin.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Clarithromycin.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Clarithromycin.Approved, Investigational
DoxycyclineThe metabolism of Clarithromycin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Clarithromycin.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Clarithromycin.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Clarithromycin.Approved, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Clarithromycin.Approved
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Clarithromycin.Approved, Investigational
EcabetThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Ecabet.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Clarithromycin.Approved
EfavirenzThe serum concentration of Clarithromycin can be decreased when it is combined with Efavirenz.Approved, Investigational
ElafinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Elafin.Investigational
ElbasvirThe metabolism of Elbasvir can be decreased when combined with Clarithromycin.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Clarithromycin.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Clarithromycin.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Clarithromycin.Approved
EnalaprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Enalapril.Approved, Vet Approved
EnalaprilatThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Enalaprilat.Approved
EnalkirenThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Enalkiren.Experimental
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Clarithromycin.Approved, Investigational
EnzalutamideThe serum concentration of Clarithromycin can be decreased when it is combined with Enzalutamide.Approved
Epigallocatechin GallateThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Epigallocatechin Gallate.Investigational
EpinastineThe metabolism of Epinastine can be decreased when combined with Clarithromycin.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Clarithromycin.Approved
EquileninThe serum concentration of Equilenin can be increased when it is combined with Clarithromycin.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Clarithromycin.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Clarithromycin.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Clarithromycin.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Clarithromycin.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Clarithromycin.Approved
EribulinEribulin may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Clarithromycin.Approved, Investigational
ErythromycinThe metabolism of Erythromycin can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
EscitalopramClarithromycin may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Clarithromycin can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Clarithromycin.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Clarithromycin.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
Estradiol acetateThe metabolism of Estradiol acetate can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
Estradiol benzoateThe metabolism of Estradiol benzoate can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
Estradiol cypionateThe metabolism of Estradiol cypionate can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
Estradiol dienanthateThe metabolism of Estradiol dienanthate can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
Estradiol valerateThe metabolism of Estradiol valerate can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Clarithromycin.Approved, Investigational
Estrogens, esterifiedThe metabolism of Estrogens, esterified can be decreased when combined with Clarithromycin.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Clarithromycin.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Clarithromycin.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Clarithromycin.Approved, Investigational
EthanolThe metabolism of Ethanol can be decreased when combined with Clarithromycin.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Clarithromycin.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Clarithromycin.Approved
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Clarithromycin.Withdrawn
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Clarithromycin.Approved, Illicit
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Clarithromycin.Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Clarithromycin.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Clarithromycin.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Clarithromycin.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Clarithromycin.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Clarithromycin.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Clarithromycin.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
FaldaprevirThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Faldaprevir.Investigational
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Clarithromycin.Approved, Investigational
FamotidineFamotidine may increase the QTc-prolonging activities of Clarithromycin.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Clarithromycin.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Clarithromycin.Approved, Investigational
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Clarithromycin.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Clarithromycin.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Clarithromycin.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Clarithromycin.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Clarithromycin.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Clarithromycin.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Clarithromycin.Approved, Investigational
FluasteroneThe serum concentration of Fluasterone can be increased when it is combined with Clarithromycin.Investigational
FluconazoleThe metabolism of Clarithromycin can be decreased when combined with Fluconazole.Approved, Investigational
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Clarithromycin.Approved, Investigational
FluindioneThe serum concentration of Fluindione can be increased when it is combined with Clarithromycin.Approved, Investigational
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Clarithromycin.Approved, Vet Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Clarithromycin.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Clarithromycin.Approved, Illicit
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Clarithromycin.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Clarithromycin.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Clarithromycin.Approved, Withdrawn
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Clarithromycin.Approved, Investigational
FluoxetineClarithromycin may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolClarithromycin may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational, Withdrawn
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Clarithromycin.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Clarithromycin.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Clarithromycin.Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Clarithromycin.Approved, Illicit, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Clarithromycin.Approved, Investigational
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Clarithromycin.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Clarithromycin.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Clarithromycin.Approved
FluvoxamineThe metabolism of Clarithromycin can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Clarithromycin.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
FosamprenavirThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Clarithromycin can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Clarithromycin.Approved
FosinoprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Fosinopril.Approved
FosnetupitantThe metabolism of Fosnetupitant can be decreased when combined with Clarithromycin.Approved
FosphenytoinThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Fosphenytoin.Approved, Investigational
FostamatinibThe metabolism of Fostamatinib can be decreased when combined with Clarithromycin.Approved, Investigational
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Clarithromycin.Approved, Investigational
Fusidic AcidThe serum concentration of Clarithromycin can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabexateThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Gabexate.Investigational
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Clarithromycin.Approved
GefitinibThe metabolism of Gefitinib can be decreased when combined with Clarithromycin.Approved, Investigational
GeldanamycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Geldanamycin.Experimental, Investigational
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Clarithromycin.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
GitoformateThe serum concentration of Gitoformate can be increased when it is combined with Clarithromycin.Experimental
GlipizideThe serum concentration of Glipizide can be increased when it is combined with Clarithromycin.Approved, Investigational
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Clarithromycin.Approved
GM6001The therapeutic efficacy of Clarithromycin can be decreased when used in combination with GM6001.Experimental
GoserelinGoserelin may increase the QTc-prolonging activities of Clarithromycin.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Clarithromycin.Approved, Investigational
GrazoprevirThe metabolism of Grazoprevir can be decreased when combined with Clarithromycin.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Clarithromycin.Approved, Investigational, Withdrawn
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Clarithromycin.Approved, Investigational
HalcinonideThe serum concentration of Halcinonide can be increased when it is combined with Clarithromycin.Approved, Investigational, Withdrawn
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Clarithromycin.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Clarithromycin.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Clarithromycin.Approved, Vet Approved
HE3286The serum concentration of HE3286 can be increased when it is combined with Clarithromycin.Investigational
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Clarithromycin.Approved
HistamineThe metabolism of Histamine can be decreased when combined with Clarithromycin.Approved, Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Clarithromycin.Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Clarithromycin.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Clarithromycin.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Clarithromycin.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Clarithromycin.Approved, Investigational
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Clarithromycin.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Clarithromycin.Approved
IbutilideClarithromycin may increase the QTc-prolonging activities of Ibutilide.Approved
IcotinibThe metabolism of Icotinib can be decreased when combined with Clarithromycin.Approved, Investigational
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Clarithromycin.Approved
IdraparinuxThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Idraparinux.Investigational
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Clarithromycin resulting in a loss in efficacy.Approved
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Clarithromycin.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Clarithromycin.Approved
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Clarithromycin.Approved, Investigational
ImidaprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be decreased when combined with Clarithromycin.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Clarithromycin.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Clarithromycin.Approved
IndapamideThe metabolism of Indapamide can be decreased when combined with Clarithromycin.Approved
IndinavirThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Indinavir.Approved
IpecacThe metabolism of Ipecac can be decreased when combined with Clarithromycin.Approved, Withdrawn
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Clarithromycin.Approved
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Clarithromycin.Approved, Investigational
IsavuconazoleThe serum concentration of Isavuconazole can be increased when it is combined with Clarithromycin.Approved, Investigational
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Clarithromycin.Approved, Investigational
IsofluraneIsoflurane may increase the QTc-prolonging activities of Clarithromycin.Approved, Vet Approved
IsoflurophateThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe metabolism of Clarithromycin can be decreased when combined with Isoniazid.Approved, Investigational
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Clarithromycin.Approved, Investigational
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Clarithromycin.Approved
IsradipineThe metabolism of Isradipine can be decreased when combined with Clarithromycin.Approved, Investigational
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Clarithromycin.Investigational
ItraconazoleThe metabolism of Clarithromycin can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Clarithromycin.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Clarithromycin.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Clarithromycin.Approved, Investigational
IxazomibThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Ixazomib.Approved, Investigational
KetamineThe metabolism of Ketamine can be decreased when combined with Clarithromycin.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Clarithromycin.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Clarithromycin.Approved, Investigational
KetoconazoleThe metabolism of Clarithromycin can be decreased when combined with Ketoconazole.Approved, Investigational
LacidipineThe serum concentration of Lacidipine can be increased when it is combined with Clarithromycin.Approved, Investigational
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Clarithromycin.Approved
Lanatoside CThe serum concentration of Lanatoside C can be increased when it is combined with Clarithromycin.Experimental
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Clarithromycin.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Clarithromycin.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Clarithromycin.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Clarithromycin.Approved
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Clarithromycin.Approved, Investigational
LepirudinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Lepirudin.Approved
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Clarithromycin.Approved, Investigational
LetaxabanThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Letaxaban.Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Clarithromycin.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Clarithromycin.Approved, Investigational
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Clarithromycin.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Clarithromycin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Clarithromycin.Approved, Investigational
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Clarithromycin.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Clarithromycin.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Clarithromycin.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Linagliptin.Approved
LisinoprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Lisinopril.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Clarithromycin.Approved, Investigational
LithiumLithium may increase the QTc-prolonging activities of Clarithromycin.Approved
LobeglitazoneThe metabolism of Clarithromycin can be decreased when combined with Lobeglitazone.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Clarithromycin.Approved, Investigational
LoperamideThe metabolism of Loperamide can be decreased when combined with Clarithromycin.Approved
LopinavirClarithromycin may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Clarithromycin.Approved, Investigational
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Clarithromycin.Approved
LorpiprazoleThe serum concentration of Clarithromycin can be increased when it is combined with Lorpiprazole.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Clarithromycin.Approved
LoteprednolThe serum concentration of Loteprednol can be increased when it is combined with Clarithromycin.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Clarithromycin.Approved, Investigational
LuliconazoleThe serum concentration of Clarithromycin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Clarithromycin.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Clarithromycin.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Clarithromycin.Illicit, Investigational, Withdrawn
MacimorelinClarithromycin may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Clarithromycin.Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Clarithromycin.Approved, Investigational
ME-609The serum concentration of ME-609 can be increased when it is combined with Clarithromycin.Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Clarithromycin.Approved, Vet Approved
Medical CannabisThe metabolism of Medical Cannabis can be decreased when combined with Clarithromycin.Experimental, Investigational
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Clarithromycin.Approved, Investigational
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Clarithromycin.Approved
MefloquineThe metabolism of Mefloquine can be decreased when combined with Clarithromycin.Approved, Investigational
MelagatranThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Melagatran.Experimental
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Clarithromycin.Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Clarithromycin.Approved, Vet Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Clarithromycin.Experimental
MethadoneThe metabolism of Methadone can be decreased when combined with Clarithromycin.Approved
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Clarithromycin.Illicit, Withdrawn
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Clarithromycin.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Clarithromycin.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Clarithromycin.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Clarithromycin.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Clarithromycin.Approved
MetildigoxinThe serum concentration of Metildigoxin can be increased when it is combined with Clarithromycin.Experimental
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Clarithromycin.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Clarithromycin.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Clarithromycin.Approved, Investigational
MianserinThe metabolism of Mianserin can be decreased when combined with Clarithromycin.Approved, Investigational
MibefradilThe metabolism of Mibefradil can be decreased when combined with Clarithromycin.Investigational, Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Clarithromycin.Approved, Illicit
MidecamycinThe metabolism of Midecamycin can be decreased when combined with Clarithromycin.Approved
MidostaurinThe metabolism of Midostaurin can be decreased when combined with Clarithromycin.Approved, Investigational
MifepristoneMifepristone may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
MifepristoneThe serum concentration of Clarithromycin can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe metabolism of Mirabegron can be decreased when combined with Clarithromycin.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Clarithromycin.Approved
MitotaneThe serum concentration of Clarithromycin can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Clarithromycin can be decreased when combined with Moclobemide.Approved, Investigational
ModafinilThe metabolism of Modafinil can be decreased when combined with Clarithromycin.Approved, Investigational
MoexiprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Moexipril.Approved
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Clarithromycin.Approved, Vet Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Clarithromycin.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Clarithromycin.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Clarithromycin.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiximolsThe metabolism of Nabiximols can be decreased when combined with Clarithromycin.Approved, Investigational
NafamostatThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Nafamostat.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Clarithromycin.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Clarithromycin.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Clarithromycin.Approved, Investigational
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Clarithromycin.Investigational
NefazodoneThe metabolism of Clarithromycin can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Nelfinavir.Approved
NeratinibThe metabolism of Neratinib can be decreased when combined with Clarithromycin.Approved, Investigational
NetupitantThe serum concentration of Clarithromycin can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Nevirapine.Approved
NicardipineThe metabolism of Nicardipine can be decreased when combined with Clarithromycin.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Clarithromycin.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Clarithromycin.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Clarithromycin.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Clarithromycin.Approved, Investigational
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Clarithromycin.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Clarithromycin.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Clarithromycin.Approved
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Clarithromycin.Approved
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Clarithromycin.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Clarithromycin.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Clarithromycin.Approved, Investigational
NitroaspirinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Nitroaspirin.Investigational
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Clarithromycin.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Clarithromycin.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Clarithromycin.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Clarithromycin.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Clarithromycin.Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Clarithromycin.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Clarithromycin.Approved
OleandrinThe serum concentration of Oleandrin can be increased when it is combined with Clarithromycin.Experimental, Investigational
Oleoyl-estroneThe serum concentration of Oleoyl-estrone can be increased when it is combined with Clarithromycin.Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Clarithromycin.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Clarithromycin.Approved
OmapatrilatThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Omapatrilat.Investigational
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Clarithromycin.Approved
OpiumThe metabolism of Opium can be decreased when combined with Clarithromycin.Approved, Illicit
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Clarithromycin.Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Clarithromycin.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Clarithromycin.Approved, Investigational
OtamixabanThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Otamixaban.Investigational
OuabainThe serum concentration of Ouabain can be increased when it is combined with Clarithromycin.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Clarithromycin.Approved
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Clarithromycin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Clarithromycin is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Clarithromycin.Approved, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Clarithromycin.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be increased when it is combined with Clarithromycin.Approved, Investigational
PaliperidoneClarithromycin may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Clarithromycin.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Clarithromycin.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Clarithromycin.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Clarithromycin.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Clarithromycin.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Clarithromycin.Approved
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Clarithromycin.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Clarithromycin.Approved, Investigational
ParoxetineParoxetine may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Clarithromycin.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Clarithromycin.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Clarithromycin.Approved, Investigational
PentobarbitalThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Clarithromycin.Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Clarithromycin.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Clarithromycin.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Clarithromycin.Approved, Investigational
PerindoprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Perindopril.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Clarithromycin.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Clarithromycin.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Clarithromycin.Approved
PeruvosideThe serum concentration of Peruvoside can be increased when it is combined with Clarithromycin.Experimental
PethidineThe metabolism of Pethidine can be decreased when combined with Clarithromycin.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Clarithromycin.Withdrawn
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Clarithromycin.Approved, Investigational
PhenobarbitalThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Phenobarbital.Approved, Investigational
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Clarithromycin.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Clarithromycin.Approved, Investigational
PhenytoinThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Phenytoin.Approved, Vet Approved
PhosphoramidonThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Phosphoramidon.Experimental
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Clarithromycin.Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Clarithromycin.Approved, Investigational
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Clarithromycin.Approved, Investigational
PimozideThe risk or severity of ventricular arrhythmias can be increased when Clarithromycin is combined with Pimozide.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Clarithromycin.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Clarithromycin.Approved, Investigational
PiperaquineThe metabolism of Piperaquine can be decreased when combined with Clarithromycin.Approved, Investigational
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Clarithromycin.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Clarithromycin.Approved
PitolisantThe serum concentration of Clarithromycin can be decreased when it is combined with Pitolisant.Approved, Investigational
PodofiloxThe metabolism of Podofilox can be decreased when combined with Clarithromycin.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Clarithromycin.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Clarithromycin.Approved, Investigational
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Clarithromycin.Approved, Investigational
PrasteroneThe metabolism of Prasterone can be decreased when combined with Clarithromycin.Approved, Investigational, Nutraceutical
Prasterone sulfateThe serum concentration of Prasterone sulfate can be increased when it is combined with Clarithromycin.Investigational
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Clarithromycin resulting in a loss in efficacy.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Clarithromycin.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Clarithromycin.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Clarithromycin.Approved, Investigational
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Clarithromycin.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Clarithromycin.Approved, Vet Approved
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Clarithromycin.Approved, Experimental, Investigational
PrimaquineThe metabolism of Primaquine can be decreased when combined with Clarithromycin.Approved
PrimidoneThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Primidone.Approved, Vet Approved
PrinomastatThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Prinomastat.Investigational
ProcainamideClarithromycin may increase the QTc-prolonging activities of Procainamide.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Clarithromycin.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Clarithromycin.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Clarithromycin.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Clarithromycin.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Clarithromycin.Approved
PropiverineThe metabolism of Propiverine can be decreased when combined with Clarithromycin.Approved, Investigational
PropofolThe metabolism of Propofol can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Clarithromycin.Approved, Investigational
ProscillaridinThe serum concentration of Proscillaridin can be increased when it is combined with Clarithromycin.Experimental
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Clarithromycin.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Clarithromycin.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Clarithromycin.Approved, Investigational
QuazepamThe metabolism of Quazepam can be decreased when combined with Clarithromycin.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Clarithromycin.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Clarithromycin.Approved, Investigational
QuinaprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Quinapril.Approved, Investigational
QuinidineClarithromycin may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
QuinineThe serum concentration of Quinine can be increased when it is combined with Clarithromycin.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Clarithromycin.Approved, Investigational
RacecadotrilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Racecadotril.Investigational
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Clarithromycin.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Clarithromycin.Approved, Investigational
RamiprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Ramipril.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Clarithromycin.Approved, Investigational
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Clarithromycin.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Clarithromycin.Approved
RemikirenThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Remikiren.Approved
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Clarithromycin.Approved, Investigational
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Clarithromycin.Approved
RibociclibThe risk or severity of QTc prolongation can be increased when Ribociclib is combined with Clarithromycin.Approved, Investigational
RifabutinThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Rifampicin.Approved
RifapentineThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Clarithromycin.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Clarithromycin.Approved
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Clarithromycin.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Clarithromycin.Approved, Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Clarithromycin.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Clarithromycin.Approved, Investigational
RitonavirThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Clarithromycin.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Clarithromycin.Approved, Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Clarithromycin.Approved, Investigational
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Clarithromycin.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Clarithromycin.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Clarithromycin.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Clarithromycin.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Clarithromycin.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Clarithromycin.Approved, Investigational, Withdrawn
RucaparibThe metabolism of Rucaparib can be decreased when combined with Clarithromycin.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Clarithromycin.Approved
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Clarithromycin.Approved
S-3304The therapeutic efficacy of Clarithromycin can be decreased when used in combination with S-3304.Investigational
SafinamideThe metabolism of Safinamide can be decreased when combined with Clarithromycin.Approved, Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Clarithromycin.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Clarithromycin.Approved
SalmeterolThe metabolism of Salmeterol can be decreased when combined with Clarithromycin.Approved
SaquinavirThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Saxagliptin.Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Clarithromycin.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Clarithromycin.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Clarithromycin.Approved, Investigational, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Clarithromycin.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Clarithromycin.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Clarithromycin.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Clarithromycin.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Clarithromycin.Approved
SiltuximabThe serum concentration of Clarithromycin can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Clarithromycin.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Clarithromycin.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Clarithromycin.Approved, Investigational
SitagliptinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Sitagliptin.Approved, Investigational
SivelestatThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Sivelestat.Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Clarithromycin.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Clarithromycin.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Clarithromycin.Approved, Investigational
SotalolClarithromycin may increase the QTc-prolonging activities of Sotalol.Approved
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Clarithromycin.Approved
SpiraprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Spirapril.Approved
St. John's WortThe serum concentration of Clarithromycin can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Clarithromycin can be increased when it is combined with Stiripentol.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Clarithromycin.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Clarithromycin.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Clarithromycin.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Clarithromycin.Approved, Vet Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Clarithromycin.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Clarithromycin.Approved, Investigational
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Clarithromycin.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Clarithromycin.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Clarithromycin.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Clarithromycin.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Clarithromycin.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Clarithromycin.Approved, Investigational
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Clarithromycin.Approved, Investigational
TasosartanThe metabolism of Tasosartan can be decreased when combined with Clarithromycin.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Clarithromycin.Experimental
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Clarithromycin.Approved, Withdrawn
TelavancinClarithromycin may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Clarithromycin can be decreased when combined with Telithromycin.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Clarithromycin.Approved, Investigational
TemocaprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Clarithromycin is combined with Temsirolimus.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Clarithromycin.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Clarithromycin.Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Clarithromycin.Approved, Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Clarithromycin.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Clarithromycin.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Clarithromycin.Approved, Investigational
Testosterone cypionateThe metabolism of Testosterone cypionate can be decreased when combined with Clarithromycin.Approved
Testosterone enanthateThe metabolism of Testosterone enanthate can be decreased when combined with Clarithromycin.Approved
Testosterone propionateThe metabolism of Testosterone propionate can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe metabolism of Testosterone undecanoate can be decreased when combined with Clarithromycin.Approved, Investigational
TetrabenazineClarithromycin may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Clarithromycin.Approved, Vet Approved
TezacaftorThe serum concentration of Tezacaftor can be increased when it is combined with Clarithromycin.Approved, Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Clarithromycin.Approved
ThioridazineClarithromycin may increase the QTc-prolonging activities of Thioridazine.Approved, Withdrawn
ThiorphanThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Thiorphan.Experimental
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Clarithromycin.Approved, Investigational
ThiothixeneThiothixene may increase the QTc-prolonging activities of Clarithromycin.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Clarithromycin.Approved, Investigational
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Clarithromycin resulting in a loss in efficacy.Approved
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Clarithromycin.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Clarithromycin.Approved, Investigational
TioclomarolThe serum concentration of Tioclomarol can be increased when it is combined with Clarithromycin.Experimental
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Clarithromycin.Approved
TipranavirThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Clarithromycin.Approved, Withdrawn
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Clarithromycin.Approved, Investigational
TocilizumabThe serum concentration of Clarithromycin can be decreased when it is combined with Tocilizumab.Approved
TocofersolanThe metabolism of Tocofersolan can be decreased when combined with Clarithromycin.Approved
TocopherolThe metabolism of Tocopherol can be decreased when combined with Clarithromycin.Approved, Investigational
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Clarithromycin.Approved, Investigational
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Clarithromycin.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Clarithromycin.Approved
TopiramateThe metabolism of Clarithromycin can be decreased when combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Clarithromycin.Approved, Investigational
ToremifeneThe risk or severity of adverse effects can be increased when Clarithromycin is combined with Toremifene.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Clarithromycin.Approved, Investigational
TramadolThe serum concentration of Tramadol can be increased when it is combined with Clarithromycin.Approved, Investigational
TrandolaprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Trandolapril.Approved
TranylcypromineThe metabolism of Clarithromycin can be decreased when combined with Tranylcypromine.Approved, Investigational
Trastuzumab emtansineThe serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Clarithromycin.Approved, Investigational
TrazodoneThe metabolism of Trazodone can be decreased when combined with Clarithromycin.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Clarithromycin.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Clarithromycin.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Clarithromycin.Approved, Investigational
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Clarithromycin.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Clarithromycin.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Clarithromycin.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Clarithromycin.Approved, Vet Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Clarithromycin.Investigational, Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Clarithromycin.Approved
UbenimexThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Ubenimex.Experimental, Investigational
UdenafilThe metabolism of Udenafil can be decreased when combined with Clarithromycin.Approved, Investigational
UlinastatinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Ulinastatin.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Clarithromycin.Approved
UlobetasolThe serum concentration of Ulobetasol can be increased when it is combined with Clarithromycin.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Clarithromycin.Approved, Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Clarithromycin.Approved, Investigational, Withdrawn
VandetanibClarithromycin may increase the QTc-prolonging activities of Vandetanib.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Clarithromycin.Investigational
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Clarithromycin.Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Clarithromycin.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Clarithromycin.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Clarithromycin.Approved, Investigational
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Clarithromycin.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Clarithromycin.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Clarithromycin.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Clarithromycin.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Clarithromycin.Approved
VildagliptinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Vildagliptin.Approved, Investigational
VinblastineThe metabolism of Vinblastine can be decreased when combined with Clarithromycin.Approved
VincamineThe serum concentration of Vincamine can be increased when it is combined with Clarithromycin.Experimental
VincristineThe serum concentration of Vincristine can be increased when it is combined with Clarithromycin.Approved, Investigational
VincristineThe metabolism of Vincristine can be decreased when combined with Clarithromycin.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Clarithromycin.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be increased when it is combined with Clarithromycin.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Clarithromycin.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Clarithromycin.Approved, Investigational
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Clarithromycin.Approved
VoriconazoleThe metabolism of Clarithromycin can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Clarithromycin.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Clarithromycin.Approved, Investigational
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Clarithromycin.Approved, Investigational
WarfarinThe metabolism of Warfarin can be decreased when combined with Clarithromycin.Approved
XimelagatranThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Ximelagatran.Approved, Investigational, Withdrawn
YohimbineThe metabolism of Yohimbine can be decreased when combined with Clarithromycin.Approved, Investigational, Vet Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Clarithromycin.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Clarithromycin.Approved, Investigational
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Clarithromycin.Approved, Illicit, Investigational
ZidovudineClarithromycin may increase the myelosuppressive activities of Zidovudine.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Clarithromycin.Approved, Investigational, Withdrawn
ZiprasidoneClarithromycin may increase the QTc-prolonging activities of Ziprasidone.Approved
ZofenoprilThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Zofenopril.Experimental
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Clarithromycin.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Clarithromycin.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Clarithromycin.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Clarithromycin.Approved
ZotepineThe metabolism of Zotepine can be decreased when combined with Clarithromycin.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Clarithromycin can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Clarithromycin.Approved, Investigational
Food Interactions
  • Biaxin - take without regard to meals (however absorption appears to be improved when drug is taken with food).
  • Biaxin XL - take with a meal, taking it on an empty stomach is associated with total product exposure 30% inferior to that observed when administered with food.

References

Synthesis Reference

Jih-Hua Liu, David A. Riley, "Preparation of crystal form II of clarithromycin." U.S. Patent US5844105, issued May, 1997.

US5844105
General References
  1. Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H: Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet. 2007 Feb 10;369(9560):482-90. [PubMed:17292768]
  2. Zuckerman JM, Qamar F, Bono BR: Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline. Infect Dis Clin North Am. 2009 Dec;23(4):997-1026, ix-x. doi: 10.1016/j.idc.2009.06.013. [PubMed:19909895]
  3. Piscitelli SC, Danziger LH, Rodvold KA: Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm. 1992 Feb;11(2):137-52. [PubMed:1312921]
  4. Peters DH, Clissold SP: Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1992 Jul;44(1):117-64. [PubMed:1379907]
  5. Authors unspecified: Clarithromycin. Tuberculosis (Edinb). 2008 Mar;88(2):92-5. doi: 10.1016/S1472-9792(08)70005-2. [PubMed:18486039]
  6. Stephenson GA, Stowell JG, Toma PH, Pfeiffer RR, Byrn SR: Solid-state investigations of erythromycin A dihydrate: structure, NMR spectroscopy, and hygroscopicity. J Pharm Sci. 1997 Nov;86(11):1239-44. [PubMed:9383733]
External Links
Human Metabolome Database
HMDB0015342
KEGG Drug
D00276
KEGG Compound
C06912
PubChem Compound
84029
PubChem Substance
46506489
ChemSpider
10342604
BindingDB
50404044
ChEBI
3732
ChEMBL
CHEMBL1741
Therapeutic Targets Database
DAP000410
PharmGKB
PA449028
HET
CTY
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Clarithromycin
ATC Codes
A02BD05 — Omeprazole, amoxicillin and clarithromycinA02BD06 — Esomeprazole, amoxicillin and clarithromycinA02BD07 — Lansoprazole, amoxicillin and clarithromycinJ01FA09 — ClarithromycinA02BD09 — Lansoprazole, clarithromycin and tinidazoleA02BD11 — Pantoprazole, amoxicillin, clarithromycin and metronidazoleA02BD04 — Pantoprazole, amoxicillin and clarithromycin
AHFS Codes
  • 08:12.12.92 — Other Macrolides
PDB Entries
1j5a / 5igj / 5igw
FDA label
Download (376 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1
0Unknown StatusBasic ScienceCancer, Breast1
1CompletedNot AvailableDrug Interaction Study1
1CompletedNot AvailableHealthy Volunteers7
1CompletedBasic ScienceAnovulatory cycle / Cytochrome P450 CYP3A Enzyme Deficiency / Disorder Due Cytochrome P450 CYP2D6 Variant1
1CompletedBasic ScienceDrug Interactions / Pharmacodynamics / Pharmacokinetics1
1CompletedBasic ScienceHealthy Volunteers2
1CompletedBasic ScienceNeoplasms / Neoplasms Metastasis1
1CompletedBasic SciencePharmacokinetics1
1CompletedBasic ScienceVenous Thromboembolism1
1CompletedScreeningOxidative Stress1
1CompletedSupportive CareHealthy Volunteers1
1CompletedTreatmentBacterial Infections / Human Immunodeficiency Virus (HIV) Infections / Mycoses1
1CompletedTreatmentDrug Interaction Potentiation1
1CompletedTreatmentHealthy Volunteers11
1CompletedTreatmentHelicobacter Pylori1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infection, Mycobacterium Avium-Intracellulare1
1CompletedTreatmentMajor Depressive Disorder (MDD)1
1CompletedTreatmentMalignant Lymphomas / Nonhematologic Malignancies1
1RecruitingBasic ScienceHealthy Volunteers1
1RecruitingTreatmentProstate Cancer1
1TerminatedBasic ScienceAdvanced Solid Tumors1
1Unknown StatusBasic ScienceHealthy Volunteers1
1, 2CompletedTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
1, 2RecruitingOtherParkinson's Disease (PD)1
1, 2RecruitingTreatmentPlasma Cell Myeloma1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
2Active Not RecruitingTreatmentMultiple Myeloma (MM)5
2Active Not RecruitingTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2CompletedNot AvailableMalignant Lymphomas1
2CompletedPreventionMultiple Myeloma and Plasma Cell Neoplasm1
2CompletedTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infection, Mycobacterium Avium-Intracellulare4
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Toxoplasmosis, Cerebral1
2CompletedTreatmentHypersomnia / Idiopathic Hypersomnia / Narcolepsy1
2CompletedTreatmentInfection, Mycobacterium Avium-Intracellulare1
2CompletedTreatmentMalignant Lymphomas2
2Not Yet RecruitingTreatmentAcid Dyspepsia / Gastritis1
2RecruitingTreatmentAppendiceal Neoplasms / Pseudomyxoma Peritonei1
2RecruitingTreatmentGastric Diffuse Large B-cell Lymphoma1
2RecruitingTreatmentInfection NOS / Multiple Myeloma (MM)1
2RecruitingTreatmentInfluenza A Virus Infection1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Non-squamous Cell Lung Cancer / Squamous Cell Carcinoma of Lung1
2RecruitingTreatmentMucosa Associated Lymphoid Tissue (MALT) Lymphoma1
2RecruitingTreatmentMultiple Myeloma (MM)1
2TerminatedPreventionUreaplasma/Mycoplasma Positive / Very Low Birth Weight Infant1
2TerminatedSupportive CareCachexia / Lung Cancers1
2TerminatedTreatmentMultiple Myeloma (MM)1
2Unknown StatusTreatmentMalignant Lymphomas1
2WithdrawnTreatmentRelapse/Refractory Multiple Myeloma1
2, 3Active Not RecruitingTreatmentMycobacterium Ulcerans Infection1
2, 3CompletedTreatmentAggressive Periodontitis1
2, 3CompletedTreatmentAggressive Periodontitis, Generalized1
2, 3Unknown StatusTreatmentDuodenal Ulcer / Gastric Ulcer (GU) / Gastritis / Helicobacter Infections1
3CompletedTreatmentAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB)1
3CompletedTreatmentAcute Bacterial Sinusitis (ABS)1
3CompletedTreatmentAcute Obliterating Bronchiolitis / Obliterative Bronchiolitis1
3CompletedTreatmentAsthma Bronchial1
3CompletedTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)2
3CompletedTreatmentCardiovascular Disease (CVD) / Heart Diseases1
3CompletedTreatmentCrohn's Disease (CD)1
3CompletedTreatmentHelicobacter Infections1
3CompletedTreatmentHelicobacter Pylori Gastritis1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infection, Mycobacterium Avium-Intracellulare4
3CompletedTreatmentPeptic ulcer haemorrhage1
3CompletedTreatmentPneumonia4
3CompletedTreatmentPneumonia, Bacterial1
3CompletedTreatmentPreterm Premature Rupture of the Membranes1
3CompletedTreatmentSepsis / Severe Sepsis / Shock, Septic1
3Not Yet RecruitingTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
3Not Yet RecruitingTreatmentLung Infection / Mycobacterium avium complex infection1
3RecruitingTreatmentAtypical; Mycobacterium, Pulmonary, Tuberculous1
3RecruitingTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)2
3RecruitingTreatmentBiomarkers / Gram-Negative Bacteria Infection / Mortality / Multiple Organ Failure / Pneumonia / Respiratory Distress Syndrome (RDS) / Sepsis1
3RecruitingTreatmentDuodenal Ulcer1
3RecruitingTreatmentHelicobacter-associated Gastritis1
3RecruitingTreatmentMultiple Myeloma (MM)3
3RecruitingTreatmentPreterm Premature Rupture of Membranes1
3TerminatedTreatmentHelicobacter Infections / Motor Fluctuations / Parkinson's Disease (PD)1
3Unknown StatusPreventionChronic Lung Disease of Prematurity1
3Unknown StatusTreatmentDuodenal Ulcer / Gastric Ulcer (GU) / Gastritis / Helicobacter Infections1
3Unknown StatusTreatmentMalignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
3Unknown StatusTreatmentMalignant Neoplasm of Stomach1
4Active Not RecruitingTreatmentHelicobacter Pylori Gastrointestinal Tract Infection1
4CompletedPreventionChronic Lung Diseases1
4CompletedTreatmentAsthma Bronchial1
4CompletedTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)6
4CompletedTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori) / Chronic Idiopathic Thrombocytopenic Purpura1
4CompletedTreatmentBorrelia Infection / Lyme Disease1
4CompletedTreatmentFunctional Dyspepsia / Helicobacter Pylori / Peptic Ulcers1
4CompletedTreatmentGastritis / Indigestion / Peptic Ulcers2
4CompletedTreatmentHelicobacter Infection1
4CompletedTreatmentHelicobacter Infections1
4CompletedTreatmentHelicobacter Pylori / Indigestion / Peptic Ulcers1
4CompletedTreatmentIndigestion / Peptic Ulcers1
4CompletedTreatmentPeptic Ulcers1
4CompletedTreatmentSepsis / Ventilator-associated Bacterial Pneumonia1
4Enrolling by InvitationTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
4Not Yet RecruitingTreatmentAntimicrobial Susceptibility Testing / Triple Therapy1
4Not Yet RecruitingTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
4Not Yet RecruitingTreatmentGastroesophageal Reflux Disease1
4Not Yet RecruitingTreatmentHelicobacter Pylori Gastrointestinal Tract Infection1
4RecruitingTreatmentAntimicrobial Susceptibility Testing / Bacterial Infection Due to Helicobacter Pylori (H. Pylori)1
4RecruitingTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)5
4RecruitingTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori) / Complications, Pregnancy / Iron Deficiency Anemia (IDA)1
4RecruitingTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori) / Gastric Polyps1
4Unknown StatusTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
4Unknown StatusTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori) / Functional Dyspepsia1
4Unknown StatusTreatmentCrohn's Disease (CD)1
4Unknown StatusTreatmentEradication Rates of the Two Regimens1
4Unknown StatusTreatmentGastritis, Gastric Ulcer, and Duodenal Ulcer1
4Unknown StatusTreatmentHelicobacter Pylori1
4Unknown StatusTreatmentMycobacterium Avium Complex Lung Disease1
4Unknown StatusTreatmentMycobacterium avium complex infection / Non-Tuberculous Mycobacteria1
Not AvailableActive Not RecruitingBasic ScienceVitamin D and Calcium Homeostasis1
Not AvailableCompletedNot AvailableHealthy Volunteers3
Not AvailableCompletedNot AvailableLower Respiratory Tract Infection (LRTI)1
Not AvailableCompletedNot AvailableRespiratory Tract Infections (RTI)3
Not AvailableCompletedSupportive CareGlomerulonephritis / Glomerulonephritis membranous / Glomerulonephritis minimal lesion1
Not AvailableCompletedTreatmentAggressive Periodontitis1
Not AvailableCompletedTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)5
Not AvailableCompletedTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori) / Functional Dyspepsia1
Not AvailableCompletedTreatmentChronic Rhinosinusitis / Endoscopic Sinus Surgery1
Not AvailableCompletedTreatmentCystic Fibrosis (CF)1
Not AvailableCompletedTreatmentGastric MALT Lymphoma1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infection, Mycobacterium Avium-Intracellulare1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Mycobacterium Avium-intracellular Infection2
Not AvailableCompletedTreatmentInfection NOS2
Not AvailableCompletedTreatmentUlcerative Colitis (UC)1
Not AvailableNot Yet RecruitingDiagnosticHyperaldosteronism1
Not AvailableRecruitingPreventionMotility Disorders / Staphylococcus Aureus1
Not AvailableRecruitingTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)5
Not AvailableRecruitingTreatmentHelicobacter Infection1
Not AvailableUnknown StatusTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Abbott Laboratories Ltd.
  • Advanced Pharmaceutical Services Inc.
  • Amerisource Health Services Corp.
  • Apotex Inc.
  • AQ Pharmaceuticals Inc.
  • A-S Medication Solutions LLC
  • Bryant Ranch Prepack
  • Cardinal Health
  • DAVA Pharmaceuticals
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Dorx LLC
  • Eon Labs
  • Gallipot
  • Genpharm LP
  • H.J. Harkins Co. Inc.
  • Innoviant Pharmacy Inc.
  • Ivax Pharmaceuticals
  • Kaiser Foundation Hospital
  • Lake Erie Medical and Surgical Supply
  • Medvantx Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Neuman Distributors Inc.
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Promex Medical Inc.
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Roxane Labs
  • Sandhills Packaging Inc.
  • Sandoz
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Stat Scripts LLC
  • Teva Pharmaceutical Industries Ltd.
  • Toba Pharma Inc.
  • UDL Laboratories
  • Watson Pharmaceuticals
  • Wockhardt Ltd.
  • Zhejiang Huayi Pharmaceutical Co. Ltd.
Dosage forms
FormRouteStrength
Tablet, extended releaseOral500 mg
Granule, for suspensionOral250 mg/5mL
Tablet, film coated, extended releaseOral500 mg/1
For suspensionOral125 mg/5mL
For suspensionOral250 mg/5mL
Granule, for suspensionOral125 mg
Granule, for suspensionOral125 mg/5mL
Granule, for suspensionOral250 mg
TabletOral250 mg/1
TabletOral500 mg/1
Tablet, coatedOral250 mg/1
Tablet, coatedOral500 mg/1
Tablet, film coatedOral250 mg/1
Tablet, film coatedOral500 mg/1
Capsule; capsule, delayed release; kit; tabletOral
Kit
TabletOral250 mg
TabletOral500 mg
Prices
Unit descriptionCostUnit
Biaxin 60 250 mg tablet Bottle379.5USD bottle
Clarithromycin 250 mg/5ml Suspension 100ml Bottle86.23USD bottle
Clarithromycin 250 mg/5ml Suspension 50ml Bottle46.56USD bottle
Clarithromycin 125 mg/5ml Suspension 100ml Bottle45.24USD bottle
Clarithromycin 125 mg/5ml Suspension 50ml Bottle27.99USD bottle
Biaxin XL 500 mg 24 Hour tablet6.77USD tablet
Biaxin xl 500 mg tablet6.57USD tablet
Biaxin 250 mg tablet6.42USD tablet
Biaxin 500 mg tablet6.37USD tablet
Clarithromycin 500 mg 24 Hour tablet5.21USD tablet
Clarithromycin er 500 mg tablet5.01USD tablet
Clarithromycin 250 mg tablet4.61USD tablet
Clarithromycin 500 mg tablet4.61USD tablet
Biaxin Bid 500 mg Tablet3.41USD tablet
Biaxin Xl 500 mg Extended-Release Tablet2.63USD tablet
Mylan-Clarithromycin 500 mg Tablet1.91USD tablet
Pms-Clarithromycin 500 mg Tablet1.91USD tablet
Ratio-Clarithromycin 500 mg Tablet1.91USD tablet
Sandoz Clarithromycin 500 mg Tablet1.91USD tablet
Biaxin Bid 250 mg Tablet1.73USD tablet
Clarithromycin 100% powder1.56USD g
Biaxin 50 mg/ml Suspension0.59USD ml
Biaxin 25 mg/ml Suspension0.3USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2471102No2005-02-082017-07-25Canada
CA1328609No1994-04-192011-04-19Canada
US6010718No1997-04-112017-04-11Us
US6551616No1997-06-152017-06-15Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)220 dec °CPhysProp
water solubility0.33 mg/LNot Available
logP3.16MCFARLAND,JW ET AL. (1997)
pKa8.99 (at 25 °C)MCFARLAND,JW ET AL. (1997)
Predicted Properties
PropertyValueSource
Water Solubility0.217 mg/mLALOGPS
logP3.18ALOGPS
logP3.24ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)12.46ChemAxon
pKa (Strongest Basic)8.38ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count13ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area182.91 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity190.79 m3·mol-1ChemAxon
Polarizability82.03 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.5434
Blood Brain Barrier-0.987
Caco-2 permeable-0.8674
P-glycoprotein substrateSubstrate0.7714
P-glycoprotein inhibitor IInhibitor0.8475
P-glycoprotein inhibitor IINon-inhibitor0.622
Renal organic cation transporterNon-inhibitor0.8987
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9161
CYP450 3A4 substrateSubstrate0.6672
CYP450 1A2 substrateNon-inhibitor0.8973
CYP450 2C9 inhibitorNon-inhibitor0.8851
CYP450 2D6 inhibitorNon-inhibitor0.9258
CYP450 2C19 inhibitorNon-inhibitor0.8835
CYP450 3A4 inhibitorNon-inhibitor0.5524
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.898
Ames testNon AMES toxic0.8967
CarcinogenicityNon-carcinogens0.9294
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7236 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9883
hERG inhibition (predictor II)Non-inhibitor0.9038
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-3900020000-7d6e24fdb4aaa06a54bd
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0005-0300060900-61dad109d1b621f69b3b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0900020000-0595f7fefa3c09c779d2
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0900000000-8a6bb2526f5f15604524
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0900000000-5d02e103d637084e4b49
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0000000900-9b3927ca525e74f19cec
MS/MS Spectrum - , positiveLC-MS/MSsplash10-052e-0800070900-da3f6b9dcca7ec506f23
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00di-0000001900-bcb836ce99019295a00e

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminoglycosides
Alternative Parents
Macrolides and analogues / O-glycosyl compounds / Oxanes / Monosaccharides / Tertiary alcohols / Trialkylamines / Secondary alcohols / 1,2-aminoalcohols / Amino acids and derivatives / Carboxylic acid esters
show 9 more
Substituents
Aminoglycoside core / Macrolide / Glycosyl compound / O-glycosyl compound / Oxane / Monosaccharide / Tertiary alcohol / 1,2-aminoalcohol / Amino acid or derivatives / Carboxylic acid ester
show 22 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
macrolide antibiotic (CHEBI:3732) / Macrolides and lactone polyketides (C06912) / Macrolides and lactone polyketides (LMPK04000014)

Targets

Kind
Protein
Organism
Shigella flexneri
Pharmacological action
Yes
Actions
Inhibitor
General Function
Structural constituent of ribosome
Specific Function
Protein L10 is also a translational repressor protein. It controls the translation of the rplJL-rpoBC operon by binding to its mRNA (By similarity).Forms part of the ribosomal stalk, playing a cent...
Gene Name
rplJ
Uniprot ID
P0A7J6
Uniprot Name
50S ribosomal protein L10
Molecular Weight
17711.38 Da
References
  1. Morimura T, Hashiba M, Kameda H, Takami M, Takahama H, Ohshige M, Sugawara F: Identification of macrolide antibiotic-binding Human_p8 protein. J Antibiot (Tokyo). 2008 May;61(5):291-6. doi: 10.1038/ja.2008.41. [PubMed:18653994]
  2. Champney WS, Burdine R: Macrolide antibiotic inhibition of translation and 50S ribosomal subunit assembly in methicillin-resistant Staphylococcus aureus cells. Microb Drug Resist. 1998 Fall;4(3):169-74. [PubMed:9818968]
  3. Zuckerman JM, Qamar F, Bono BR: Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline. Infect Dis Clin North Am. 2009 Dec;23(4):997-1026, ix-x. doi: 10.1016/j.idc.2009.06.013. [PubMed:19909895]
  4. Authors unspecified: Clarithromycin. Tuberculosis (Edinb). 2008 Mar;88(2):92-5. doi: 10.1016/S1472-9792(08)70005-2. [PubMed:18486039]
  5. Champney WS, Burdine R: Macrolide antibiotics inhibit 50S ribosomal subunit assembly in Bacillus subtilis and Staphylococcus aureus. Antimicrob Agents Chemother. 1995 Sep;39(9):2141-4. [PubMed:8540733]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Keseru GM: Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg Med Chem Lett. 2003 Aug 18;13(16):2773-5. [PubMed:12873512]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP: Structure-based identification of OATP1B1/3 inhibitors. Mol Pharmacol. 2013 Jun;83(6):1257-67. doi: 10.1124/mol.112.084152. Epub 2013 Apr 9. [PubMed:23571415]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
References
  1. De Bruyn T, van Westen GJ, Ijzerman AP, Stieger B, de Witte P, Augustijns PF, Annaert PP: Structure-based identification of OATP1B1/3 inhibitors. Mol Pharmacol. 2013 Jun;83(6):1257-67. doi: 10.1124/mol.112.084152. Epub 2013 Apr 9. [PubMed:23571415]

Enzymes

Details
1. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zuckerman JM, Qamar F, Bono BR: Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline. Infect Dis Clin North Am. 2009 Dec;23(4):997-1026, ix-x. doi: 10.1016/j.idc.2009.06.013. [PubMed:19909895]
  2. Authors unspecified: Clarithromycin. Tuberculosis (Edinb). 2008 Mar;88(2):92-5. doi: 10.1016/S1472-9792(08)70005-2. [PubMed:18486039]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA: Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002 Aug;30(8):883-91. [PubMed:12124305]
  5. Fontana E, Dansette PM, Poli SM: Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab. 2005 Oct;6(5):413-54. [PubMed:16248836]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
Gene Name
SLC22A7
Uniprot ID
Q9Y694
Uniprot Name
Solute carrier family 22 member 7
Molecular Weight
60025.025 Da
References
  1. Kobayashi Y, Sakai R, Ohshiro N, Ohbayashi M, Kohyama N, Yamamoto T: Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22. Epub 2005 Feb 11. [PubMed:15708966]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674]
  2. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514]
  3. Egashira K, Ohtani H, Itoh S, Koyabu N, Tsujimoto M, Murakami H, Sawada Y: Inhibitory effects of pomelo on the metabolism of tacrolimus and the activities of CYP3A4 and P-glycoprotein. Drug Metab Dispos. 2004 Aug;32(8):828-33. [PubMed:15258108]
  4. Authors unspecified: Clarithromycin. Tuberculosis (Edinb). 2008 Mar;88(2):92-5. doi: 10.1016/S1472-9792(08)70005-2. [PubMed:18486039]
  5. Dey S, Gunda S, Mitra AK: Pharmacokinetics of erythromycin in rabbit corneas after single-dose infusion: role of P-glycoprotein as a barrier to in vivo ocular drug absorption. J Pharmacol Exp Ther. 2004 Oct;311(1):246-55. Epub 2004 Jun 2. [PubMed:15175422]

Drug created on June 13, 2005 07:24 / Updated on May 22, 2018 23:50